Appropriate Surrogate Endpoint in Drug-Coated Balloon Trials for Coronary Artery Diseases

BACKGROUND: The appropriateness of using late lumen loss (LLL) as a surrogate endpoint was established in drug-eluting stent (DES) studies, but it was less supportive for drug-coated balloon (DCB) trials. METHODS: Studies published until 23 June 2021 were searched from PubMed, EMBASE, Cochrane Libra...

Descripción completa

Detalles Bibliográficos
Autores principales: Lang, Xinyue, Wang, Yang, Li, Wei, Liu, Xiaoyun, Zhao, Yanyan, Wang, Chuangshi, Li, Xiaocong, Zhu, Yingxuan, Li, Mengya, Song, Lei, Xu, Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9256952/
https://www.ncbi.nlm.nih.gov/pubmed/35811708
http://dx.doi.org/10.3389/fcvm.2022.897365

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9256952/
https://www.ncbi.nlm.nih.gov/pubmed/35811708
http://dx.doi.org/10.3389/fcvm.2022.897365

Ejemplares similares